OLMA

Olema Pharmaceuticals, Inc.

Healthcare
Biotechnology
$893M market cap

Forecast run · Sep 14, 2026Upside rank 762 of 3,136

Model Signal

ForecastQ Daily Probabilities

49.6%

38.6%

27.2%

Analyst Consensus

Recommendation2.00/5 Buy

Last price$10.22

Price target$27.50

Implied move+169.1%

Analysts8

ForecastQ Portfolios

OLMA is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Olema Pharmaceuticals, Inc., a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. Headquartered in San Francisco, California, the company was established in 2006 and rebranded from CombiThera, Inc. in March 2009. Its most promising investigational compound, OP-1250, an estrogen receptor (ER) antagonist and selective ER degrader, is presently undergoing Phase 1/2 clinical evaluations. This drug candidate is being assessed for its efficacy in managing recurrent, locally advanced, or metastatic breast cancer that expresses estrogen receptors but is negative for human epidermal growth factor receptor 2.